|
|
|
|
Fibrobiologics Inc (NASDAQ: FBLG) |
|
Price: $1.1000
$-0.01 
-0.901%
|
| Day's High:
| $1.14
| Week Perf:
| 7.84 %
|
| Day's Low: |
$ 1.09 |
30 Day Perf: |
2.8 % |
| Volume (M): |
83 |
52 Wk High: |
$ 13.59 |
| Volume (M$): |
$ 91 |
52 Wk Avg: |
$3.14 |
| Open: |
$1.13 |
52 Wk Low: |
$0.95 |
|
|
| Market Capitalization (Millions $) |
37 |
| Shares
Outstanding (Millions) |
34 |
| Employees |
11 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-8 |
| Cash Flow (TTM) (Millions $) |
-1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Fibrobiologics Inc
Company Address: 455 E. Medical Center Blvd Houston 77598 TX
Company Phone Number: 651-5150 Stock Exchange / Ticker: NASDAQ FBLG
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Stock Market Announcement
Published Mon, Dec 30 2024 9:30 PM UTC
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing Amid Strategic CollaborationsHOUSTON, Dec. 30, 2024 FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company recognized for its innovative therapies targeting chronic diseases, has successfully closed the second $5 million tranche of a previously announced Standby Equity Purchase A...
|
| Partnership
Published Thu, Sep 19 2024 1:31 PM UTC
Abstract: FibroBiologics, a pioneering company in the field of regenerative medicine, has recently engaged Southern Star Research as its Clinical Research Organization (CRO) in Australia. This partnership aims to facilitate the development of innovative therapies based on fibroblast technology. The engagement underscores the growing importance of strategic collaborations i...
|
| Product Service News
Published Tue, Jun 25 2024 1:31 PM UTC
FibroBiologics Unveils Groundbreaking Thymus Organoid Technology: A Milestone in Immune Restoration In a stride that could redefine therapeutic approaches to immune disorders, FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, announced a pioneering development in regenerative medicine. On June 25, 2024, the company revealed successful preliminary p...
|
| Product Service News
Published Thu, Jun 13 2024 1:31 PM UTC
Entry into the Russell 2000 Amplifies Company?s Market Presence and Growth Potential HOUSTON, June 13, 2024 FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company dedicated to pioneering therapeutics and potential cures for chronic diseases through the use of fibroblasts and fibroblast-derived materials, has announced its forthcoming inclusion in the...
|
| Clinical Study
Published Thu, Apr 4 2024 1:31 PM UTC
for Date: Insert Current DateFibroBiologics, Inc., a clinical-stage biotechnology company specializing in the development of therapeutics for chronic diseases, has recently released data from a study exploring the therapeutic potential of dermal fibroblast spheroids in the treatment of chronic wounds. The study, conducted in a diabetes mouse model, aims to shed light on th...
|
| Per Share |
Current |
| Earnings (TTM) |
-0.25 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
0.23 $
|
| Book Value |
0.08 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.25 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
0.23 $
|
| Book Value |
0.08 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
0.82%